1. A Pharmacist's Guide to Safety and Use of Immune Checkpoint Inhibitors

2. Program Overview

3. Immune Checkpoint Inhibitors

4. CTLA-4 and PD-1 Pathway Blockade

5. Immune Checkpoint Inhibitors (cont)

6. Approved Indications for ICP Inhibitors as of December 2018

7. Approved Indications for ICP Inhibitors as of December 2018 (cont)

8. Approved Indications for ICP Inhibitors as of December 2018 (cont)

9. Checkpoint Inhibitor Toxicities

10. Management of irAEs in Patients Treated With ICP Inhibitors

11. Management of irAEs in Patients Treated With ICP Inhibitors (cont)

12. Rash/Inflammatory Dermatitis

13. Colitis (Highlights)

14. Hypothyroidism (Highlights)

15. Pneumonitis

16. Immunotherapy irAE Summary

17. Patient Case

18. Counseling Patients

19. Counseling the Healthcare Team

20. Case (cont)

21. Discussion

22. Key Pharmacy Interventions and Counseling

23. Follow-Up

24. Important Prescribing Considerations

25. Important Prescribing Considerations (cont)

26. Important Prescribing Considerations (cont)

27. Conclusions

28. Abbreviations

29. Abbreviations (cont)